After Intellia Therapeutics paused a pair of phase 3 trials for its CRISPR therapy in response to a liver safety signal, the ...
The FDA has granted fast track designation to JSKN003, a biparatopic HER2-targeting antibody-drug conjugate (ADC), for the ...
LOUISVILLE, Colo., Feb. 24, 2025 /PRNewswire/ - (TSX: CWEB) (OTCQX: CWBHF) Charlotte's Web Holdings, Inc. ("Charlotte's Web" or the "Company"), a market leader in hemp extract wellness products, is ...
The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to DPTX3186, an investigational therapy being ...
The agency will no longer require studies comparing copycat biologics to their branded counterparts, which could help ...
The biotech’s phase 3 delivered the hoped-for second biomarker hit, reporting an 82% decline in serum creatine kinase after ...
BOSTON, Mass, April 01, 2025 (GLOBE NEWSWIRE) -- Radiance Biopharma, Inc. (“Radiance” or the “Company”), a clinical stage biopharmaceutical company advancing Antibody Drug Conjugates (‘ADCs’), today ...
Edesa Biotech has announced positive results from a Phase III clinical trial of its drug candidate, paridiprubart (EB05), for ...
4D Molecular Therapeutics has initiated its first Phase 3 trial for 4D-150 in wet AMD and expanded its clinical pipeline. 4D Molecular Therapeutics (4DMT) has announced significant progress in its ...
The FDA placed a clinical hold on BioNTech’s Phase 1/2a trial for its investigational RNA-based malaria vaccine, BNT165e. BioNTech paused the study and is working with the FDA to address its requests ...
Tempest Therapeutics, Inc. has announced that the U.S. FDA has granted a "Study May Proceed" letter for their Phase 2 clinical trial of TPST-1495, a novel dual receptor inhibitor aimed at treating ...
Milestone advances MEAI-based therapy targeting a global Alcohol Use Disorder treatment market projected to surpass $20 billion by 2032 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback